TL011 in Severe, Active Rheumatoid Arthritis Patients
A Phase Ib Study Evaluating Safety, Pharmacokinetic and Pharmacodynamic Profiles of a Single Course of TL011 Infusions in Subjects With Severe, Active Rheumatoid Arthritis
Sponsor: Teva Pharmaceutical Industries, Ltd.
Listed as NCT01123070, this PHASE1 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Teva Pharmaceutical Industries, Ltd., it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2021 — Jan 2022 [monthly]
Completed PHASE1
Phase: PHASE1_PHASE2 → PHASE1
▶ Show 3 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Pharmaceutical Industries, Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barakaldo, Spain , Budapest, Hungary , Debrecen, Hungary , Florence, Italy , Genova, Italy , Guadalajara, Spain , Madrid, Spain , Manchester, United Kingdom , Pavia, Italy , Pilsen, Czechia and 7 more locations